PAMA Unlocks Golden Age for Innovative Diagnostics

PAMA Unlocks Golden Age for Innovative Diagnostics

By Chance Scott  bio
The publication of the 2018 Clinical Laboratory Fee Schedule (CLFS) in January saw a long and heated debate within the lab community come to fruition…


. . . read more

Venture Capital Investment in Diagnostic Companies Strong in 2017

Venture Capital Investment in Diagnostic Companies Strong in 2017

From - Diagnostic Testing & Emerging Technologies
Venture capital investments in health care innovation reached an all time high in 2017, including in diagnostics/tools (Dx/Tools) companies, according to…


. . . read more

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here

FDA Speeding Approval Process, Continued User Fees Needed

From - Diagnostic Testing & Emerging Technologies
The U.S. Food and Drug Administration (FDA) is plagued with chronic understaffing, scrutiny over the length of time for approvals, and an expanding workload, while also…


. . . read more

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here